哈尔满盐酸盐 | 21655-84-5

• 物质功能分类: 生物化工 - 提取物
• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 中文名称: 哈尔满盐酸盐
• 中文别名: 盐酸哈尔满；盐酸-2-甲基-Β-咔啉；1-甲基-9H-吡啶并[3,4-B]吲哚盐酸盐；牛角花碱盐酸盐
• 英文名称: harmane hydrochloride
• 英文别名: harman hydrochloride；harmane；hydron;1-methyl-9H-pyrido[3,4-b]indole;chloride
• CAS: 21655-84-5
• 化学式: C₁₂H₁₀N₂*ClH
• mdl: MFCD00012640
• 分子量: 218.686
• InChiKey: COVNOIRYDKHLJD-UHFFFAOYSA-N

物化性质

• 熔点：
  290°C
• 稳定性/保质期：
  <p><b><br/></b></p>

计算性质

• 辛醇/水分配系数(LogP)：
  2.0
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  28.7
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090
• 储存条件：
  <p><br></p>

制备方法与用途

合成制备方法
用途

反应信息

• 作为反应物：
  描述：

  哈尔满盐酸盐 、 2,6-蒽二酚 在 phosphate buffer pH 5.5 作用下， 以 水 为溶剂， 生成
  参考文献：
  名称：

  Spectroscopic study of molecular associations between FMN and β-carbolines

  摘要：

  The spectrophotometric and thermodynamic properties of molecular complexes of flavin mononucleotide (FMN) (riboflavin 5'-phosphate) with some beta-carboline derivatives have been investigated in aqueous solution. The molecular associations have been examined by means of electronic absorption spectra, since in each a new charge-transfer band has been located, and also the variation of the fluorescence emission of FMN on the solutions has been observed. The formation constants for the molecular complexes were determined from absorption data using the Foster-Hammick-Wardley method. The quenching phenomenon observed in FMN fluorescence is related to the concentration of the beta-carboline derivatives, allowing the calculation of the quenching constants for FMN-beta-carboline complexes. Thermodynamic parameters have been determined from the values of association constants for the molecular complexes at various temperatures. The influence of substituents in the beta-carboline molecule on the stability of the complexes formed was also investigated.

  DOI：

  10.1016/0584-8539(93)80248-9

文献信息

• METHODS AND COMPOSITIONS FOR TREATING INFECTION
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US20150238473A1

  公开（公告）日：2015-08-27

  Provided herein are compositions and methods for treating or preventing infection.

  本文提供了用于治疗或预防感染的组合物和方法。
• Small molecule toll-like receptor (TLR) antagonists
  申请人：Lipford B. Grayson

  公开号：US20050119273A1

  公开（公告）日：2005-06-02

  The invention provides methods and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a small molecule having a core structure including at least two rings. Certain of the compounds are 4-primary amino quinolines. Many of the compounds and methods are useful specifically for inhibiting immune stimulation involving at least one of TLR9, TLR8, TLR7, and TLR3. The methods may have use in the treatment of autoimmunity, inflammation, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer, and immunodeficiency.

  本发明提供了用于调节通过Toll样受体信号传导的方法和组合物。该方法涉及使用含有至少两个环的核心结构的小分子与表达TLR的细胞接触。其中某些化合物是4-主氨基喹啉。许多化合物和方法特别适用于抑制涉及至少一个TLR9、TLR8、TLR7和TLR3的免疫刺激。该方法可用于治疗自身免疫、炎症、过敏、哮喘、移植排斥、移植物抗宿主病、感染、败血症、癌症和免疫缺陷。
• Methods and compositions for treating infection
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US10004701B2

  公开（公告）日：2018-06-26

  Provided herein are compositions and methods for treating or preventing infection.

  本文提供了用于治疗或预防感染的组合物和方法。
• Pharmaceutical Compositions Comprising Beta-Carboline Derivatives and Use Thereof for the Treatment of Cancer
  申请人：Jossang born Yanagida Akino

  公开号：US20080069899A1

  公开（公告）日：2008-03-20

  The invention relates to the use of at least one compound of general formula (1) for the production of a medicament for the treatment of cancer.
• Chemical Proteomic Assay for Optimizing Drug Binding to Target Proteins
  申请人：Sem Daniel S.

  公开号：US20100304998A1

  公开（公告）日：2010-12-02

  Disclosed herein are methods related to drug development. The methods typically include steps whereby an existing drug is modified to obtain a derivative form or whereby an analog of an existing drug is identified in order to obtain a new therapeutic agent that preferably has a higher efficacy and fewer side effects than the existing drug.